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Abstract
Purpose This is the first prospective trial evaluating the efficacy of alpha emitter Radium-223 in patients with bone metastases
from radioactive iodine (RAI) refractory (RAIR) differentiated thyroid cancer.
Methods RADTHYR is a multicenter, single-arm prospective Simon two-stage phase II trial (NCT02390934). The primary
objective was to establish the efficacy of three administrations of 55 kBq/kg of Radium-223 by 18F-FDG PET/CT according to
PERCIST criteria. Secondary objectives were to establish the efficacy of six administrations of Radium-223 by 18F-FDG PET/CT,
99mTc-HMDP bone scan and 18FNa PET/CT, clinical benefits, changes in serum bone markers, thyroglobulin levels, and safety.
Results Ten patients were enrolled between July 2015 and December 2017 (4 M; median age 74 years). Prior to Radium-223
administration, patients received a median RAI cumulative activity of 15 GBq (7.4–35.6), external radiation therapy (n = 9), bone
surgery (n = 8), cimentoplasty (n = 5), and cryoablation (n = 2). 18F-FDG PET/CT showed stable disease (SD) in 4/10 and
progressive disease (PD) in 6/10 cases after three administrations and SD in 4/10, PD in 5/10 cases, and 1/10 non-evaluable
(NE) case after six administrations. After six injections, 99mTc-HMDP bone scan showed SD in 9 cases and was NE in 1 case;
18FNa PET/CT showed SD in 8 cases, partial response (PR) in 1 case, and was NE in 1 case. No significant clinical benefits were
reported during the study. A skeletal event occurred in 6 patients (median time without skeletal event of 12.1 months). Seventy-
seven adverse events were reported during treatment (7 of grade 3–4). Three patients developed an acute myeloid, a
promyelocytic, and a chronic myeloid leukemia after the last Radium-223 administration considered as drug-related.
Conclusion The trial was stopped after interim analysis for lack of response of bone metastases from RAIR thyroid cancer to
Radium-223. Severe hematological toxicity was observed in patients heavily pretreated with RAI and external radiation.
Trial registration number NCT02390934. Registration date 18.03.2015.
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Introduction
Distant metastases occur in 4 to 10% of patients with differen-
tiated thyroid cancer (DTC) [1]. When present, the 5-year sur-
vival ranges from 78% in patients with single-organ metastasis
to 15% in patients with multi-organ metastases [1–3].
Radioactive iodine (RAI) remains the milestone for the treat-
ment of patients with distant metastases and a prompt identifi-
cation is necessary. Bone lesions are present in 20–40 % of
patients with distant metastases; they can be synchronous or
metachronous to primary thyroid tumor diagnosis and are the
most challenging metastases to treat [4]. They can be lytic,
sclerotic, or mixed with a combined lytic and sclerotic aspect
on imaging. In cases of small size lesions and in the presence of
RAI uptake, complete response can be achieved [5]. However,
bone lesions are often large with soft tissue infiltration, poor
response to RAI, or progressive loss of RAI uptake with sub-
sequent worst prognosis especially when present since the be-
ginning of the clinical history [4, 6]. Local treatments such as
surgery, external beam radiation, thermoablation, and cement
injection may prevent skeletal-related events as well as bone
resorption inhibitors such as denosumab or bisphosphonates
[7–9]. However, the rapid occurrence of bone events remains
frequent, occurring in one third of patients with bone metasta-
ses, highlighting the need for specific bone treatments [10].
Radium-223 is an alpha emitter radionuclide with a biolog-
ical effect characterized by DNA double-strand breaks with cell
apoptosis and a high cytotoxic effect. It shares similar chemical
properties with calcium, and its uptake in bone matrix is corre-
lated with bone remodeling. Radium-223 (Xofigo®) was ap-
proved by the Food and Drug Administration (FDA) and by the
European Medical Agency (EMA) for the treatment of symp-
tomatic bone metastases from castration-resistant prostate can-
cer, based on improvement in overall survival in a phase III trial
[11]. Patients with prostate cancer mostly have sclerotic bone
lesions, a favorable setting for the efficacy of Radium-223,
since it preferably accumulates in these lesions with a subse-
quent good control of pain and longer PFS especially in patients
with low tumor burden [12]. However, preliminary data on
breast cancer showed its potential effectiveness in a setting of
mixed and lytic lesions [13–16].
The aim of this phase II trial was to evaluate for the first
time the efficacy and the tolerance of Radium-223 treatment
in patients with bone metastases from RAI refractory (RAIR)
DTC and not candidate for target therapy or local treatments.
Materials and methods
Study design
The RADTHYR study was a prospective, multicenter, open-
label phase II trial (ClinicalTrials.gov number NCT02390934)
of Radium-223 in patients with bone metastases from RAIR
DTC approved by the local institutional board of Gustave
Roussy, Institut Universitaire du Cancer Toulouse Oncopole
and Groupement Hospitalier Est of Bron. The primary objec-
tive was to evaluate the efficacy of three monthly Radium-223
administrations by 18F-Fluorodeoxyglucose positron emission
tomography/computed tomography (18F-FDG PET/CT) ac-
cording to PET Response Criteria In Solid Tumor
(PERCIST) [17].
The secondary objectives were to (1) evaluate the efficacy
of six monthly administrations of Radium-223 by 18F-FDG
PET/CT according to PERCIST criteria; (2) evaluate monthly
the clinical benefits during treatment; (3) evaluate the time to
occurrence of skeletal events; (4) evaluate the response on
99mTc-hydroxymethylene diphosphonate (HMDP) bone scan
and on sodium-fluoride (18FNa) PET/CT after three and six
monthly administrations of Radium-223; (5) describemonthly
changes in serum alkaline phosphatase (ALP), bone-ALP (b-
ALP), and thyroglobulin (Tg) during Radium-223 administra-
tion; and 6) assess the safety of Radium-223 according to NCI
CTCAE version 4.
Patient selection
The main inclusion criteria were as follows: (1) histolog-
ically confirmed DTC (papillary, follicular, Hurthle cell,
or poorly differentiated); (2) metastatic RAIR refractory
disease (absence of RAI uptake in metastatic lesions or in
case of RAI uptake present in some but not in other tumor
foci or progression of the disease within 14 months after
RAI administration treatment or persistent disease after
the administration of a cumulative activity of 22 GBq;
(3) age ≥ 18 years; (4) Eastern Cooperative Oncology
Group (ECOG) performance status 0–2; (5) presence of
at least one bone metastasis visible on CT scan and not
needing imminent local treatment; (6) stable disease with-
in 6 months before inclusion and low likelihood of an
indication for systemic treatment within the next 6 months;
(7) absence of visceral metastases or visceral metastases
stable within 6 months before inclusion according to mor-
phological imaging; (8) presence of at least one bone me-
tastasis with uptake on 18F-FDG PET/CT; (9) presence of
at least one bone metastasis with increased uptake on
99mTc- HMDP bone scintigraphy or on 18FNa PET/CT;
and (10) adequate hematological parameters. Patients re-
ceiving bisphosphonates or anti-receptor activator of nu-
clear factor κ (RANK) ligand were allowed but patients
should have received at least two administrations prior to
Radium-223 administration, and these treatments were
continued during Radium-223 treatment. The complete
lists of inclusion and exclusion criteria are presented in
Supplementary Table 1.
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Protocol
Radium-223 (55kBq/kg, IV) was administered according to
the international guidelines every 4 weeks for 3 months [18].
In the absence of severe adverse events, skeletal-related
events, or appearance of new lesions at 18F-FDG PET/CT,
further three monthly Radium-223 injections were adminis-
tered. If only an increase of uptake of 18F-FDG occurred in the
existing lesions after three administrations of Radium-223, the
treatment was continued.
A functional and morphological evaluation (including an
18F-FDG PET/CT, 99mTc-HMDP bone scan, 18FNa PET/CT)
was performed within 4 to 8 weeks prior to Radium-223 treat-
ment initiation, and then 1 month after the third and the sixth
administration. Clinical and biological (hematology, bio-
chemistry, and thyroglobulin) evaluations were performed
each month before Radium-223 administration to assess the
clinical benefits and toxicity. After the last Radium-223 treat-
ment, patients were followed every 3 months until 12 months.
Patients performed all PET/CT and bone scintigraphies in the
same center. Radium-223 continuation was decided locally
while all PET images (both 18F-FDG and 18FNa) and bone
scans were centrally reviewed by the same expert physician in
nuclear medicine (D.D).
Imaging protocols
18F-FDG PET/CT was performed after a 6-h fast, in case of
plasma glucose level < 10mmol/L prior to 18F-FDG injection,
with administration of a maximal 18F-FDG activity of 3.5
MBq/kg. PET images were performed 60 ± 10min after tracer
injection and recorded from the apex of the skull to the mid-
thighs in 3Dmode, 7–10 bed, 2 min/bed position. 18FNa PET/
CT images were performed 60 ± 10 min after injection of a
maximal activity of 3.5MBq/kg and whole-body images were
recorded in 3D mode, 7–10 bed, 2 min/bed position. Prior to
PET images a whole-body low-dose CT acquisition for atten-
uation correction and anatomical correlation was performed.
Images were reconstructed using an iterative algorithm
(FORE and AWOSEM) and a time of flight (TOF) technique.
99mTc HMDP Bone scan was performed with anterior/
posterior whole-body planar images recorded on a double-
headed gamma camera 3 h after the administration of
10 MBq/kg and additional single photon emission tomogra-
phy (SPECT/CT) was carried out in indeterminate abnormal-
ities. For each patient, both 18F-FDG PET and 18FNa PET and
bone scintigraphy were performed on the same scanner and
with the same time/activity protocol (Discovery 690 PET/CT
and Discovery 670 SPECT/CT, GE Healthcare for Gustave
Roussy, GE Discovery IQ and GEDiscovery NMCT 670 GE
Healthcare for Toulouse; Siemens Biograph mCT 64 and
Symbia T2 SPECT/CT for Bron). The PET/CT scanners
employed in the study had an active EARL accreditation in
all centers.
Evaluation criteria
A detailed summary of the evaluation criteria is available in
Supplementary Table 2. Because RECIST 1.1 does not apply
to bone evaluation, response evaluation was based on meta-
bolic response assessed 1 month after three monthly (primary
objective) and six monthly (secondary objective) injections of
Radium-223 on 18F-FDG PET/CT according to PERCIST
[17]. Lean body mass corrected total standardized uptake val-
ue (SUL) peak in up to five lesions with the highest 18F-FDG
uptake was considered the main criteria for disease response.
The total lesion glycolysis (TLG) defined as SUVmean ×
functional volume (FV) was considered for progressive dis-
ease (PD) definition as proposed by PERCIST. Pure bone
lesion without extension to soft tissue, without metallic part,
not previously treated with radiotherapy or focal treatment
were considered target lesions. The total SUVmax was con-
sidered the main criteria for functional changes assessment in
up to five lesions with the highest 18FNa PET/TC uptake. All
lesions were manually segmented by drawing a spherical vol-
ume of interest (VOI) and the semiquantitative parameters
were extracted by an automated dedicated multivendor soft-
ware for imaging analysis. A 40% threshold was settled for
SUVmax. For 99mTc HMDP bone scan evaluation, a visual
analysis was performed.
Clinical benefits were evaluated monthly, and data were
compared to baseline examinations. These included pain re-
sponse, based on the numerical visual analogue pain scale
rating from 0 to 10 completed by the patient; furthermore,
the improvement of ECOG performance status was consid-
ered. Serum thyroglobulin (Tg) in the absence of Tg antibod-
ies (Ab), alkaline phosphatase (ALP), and bone-ALP changes
was determined monthly and compared to baseline values.
The skeletal-related event definition included local progres-
sion with indication for focal treatment and/or pathological
fracture and/or spinal cord compression. Adverse events and
their grade were assessed according to the National Cancer
Institute Common Terminology Criteria for AEs, version
4.0. Twelve months of safety monitoring after the last admin-
istration were planned for all patients who received at least
one Radium-223 injection.
Statistical analysis
The study was conducted according to a Simon minimax two-
stage design to allow early termination of the trial for lack of
efficacy [19]. Sample size was calculated on the hypothesis
that a probability of 15% was the minimal response rate and a
probability of 40% was the expected response rate, with a
power of 80% and a type I error rate of 5%. Nine patients
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had to be enrolled in the first stage, and the study continued to
19 patients only if at least two of the nine patients showed a
metabolic response. At the end of the study, if six metabolic
responses or more were noticed, the treatment could be con-
sidered effective.
The scientific committee decided to stop the inclusions
after the first stage, according to the interim analysis showing
zero responders among the first nine patients included.
Because of the impossibility of stopping recruitment until
the observation of the 3-month primary endpoint, one addi-
tional patient was included before the study discontinuation
was decided. We present herein the results of the statistical
analyses performed on the whole study population (ten pa-
tients). Continuous variables were described as standard sum-
mary statistics, such as number of observations, median, and
range. Categorical variables were summarized in frequency
tables as counts and percentages. Time to skeletal-related
events was calculated as the interval of time between inclusion
and the occurrence of skeletal-related events or the last follow-
up date if no skeletal-related event occurred. Overall survival
(OS) was defined as time from inclusion to death due to any
cause or the date of the last follow-up for alive patients. Time-
to-event variables were estimated using the non-parametric
Kaplan-Meier method.
Results
A total of 13 patients were assessed for eligibility (Fig. 1).
Three screened patients failed because of the absence of 18F-
FDG uptake at baseline (n = 2) or because of imminent
cimentoplasty needed (n = 1).
Ten patients were enrolled between July 2015 and
December 2017 (4M/6F; median age 74 years), at Gustave
Roussy (n = 5), at Institut Universitaire du Cancer Toulouse
Oncopole (n = 3) and at Groupement Hospitalier Est of Bron
(n = 2). The main initial characteristics of the patients are pre-
sented in Table 1. The median time since the first bone me-
tastasis discovery was 6 years. They received a median of 4
RAI administrations before inclusion, with a median cumulat-
ed activity of 15 GBq (range: 7.4–35 GBq). At least one pre-
vious bone treatment had been given to each patient consisting
of external radiation therapy (n = 9), bone surgery (n = 8),
cimentoplasty (n = 5), and cryoablation (n = 2). Three patients
were treated with bisphosphonates and two with RANK-
ligand inhibitors prior to inclusion. None of the patients re-
ceived tyrosine kinase inhibitors prior to inclusion.
Treatment
Nine of the 10 patients received six cycles of Radium-223,
whereas Radium-223 treatment was stopped after three cycles
in one patient because surgery was then indicated for a skeletal
event.
Metabolic response
At baseline 18F-FDG PET/CT, a median number of 4 lesions
(range 1–11) including axial and peripheral skeleton was de-
tected. Eight out of ten patients had less than 10 lesions (10
and 11, respectively, in the two remaining cases). A total of 28
bone lesions (range: 1–5), in accordance with the target le-
sions selection criteria, were evaluable on 18F-FDG PET/CT
for SUL peak and TLG calculation according to PERCIST
and considered for analysis. Among the 28 lesions, 15 were
classified as lytic lesions, 10 asmixed lesion, and 2 as sclerotic
lesions and 1 was not clearly visible on CT but with high
18FDG uptake. The median baseline SUL peak per lesion
was 3.2 (range: 1.1–29.6) and the median total SULpeak
was 10.0 (2.2–51.6); the median TLG for lesion was 21.3
(range :1.7– 283) and the median total TLG was 122.8 (range:
13–530), respectively. After three administrations of Radium-
223, disease was defined as stable (SD) in 4 cases and pro-
gressive (PD) in 6 cases according to SUL peak and/or TLG.
After six administrations of Radium-223, in the 9 evaluable
patients, response was SD in 4 cases and PD in 5 cases (Fig.
2). One patient (patient n = 10) classified as PD for a signifi-
cant increase of TLG in targets lesions at 3 months was clas-
sified as SD at 6 months. Another patient (patient n = 4) with
Fig. 1 Consolidated standards of
reporting trials (CONSORT)
DIAGRAM of the study
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both bone and lung lesions was defined as PD at 3 months for
a significant increase of uptake in target lesions but as SD at
6 months at a bone level; finally, he was defined as PD for the
appearance of a new lung lesion. The remaining 5/6 patients
who presented at inclusion distant metastases in other sites
(neck and lung) did not show during the 6-month treatment
any progression in visceral metastases at 18F-FDG PET/CT.
Patients classified at 6 months as PD had papillary (n = 2),
follicular (n = 1), poorly differentiated (n = 1), and Hurthle
cells (n = 1) carcinoma, while patients classified as SD had
papillary (n = 3) and follicular (n = 1) carcinoma, respectively.
The median cumulative activity of radioactive iodine previ-
ously received was 14.8 GBq (range :11.1–25.9) in patients
with PD and 24.9 GBq (range:7.4–35.6) in patients with SD,
Table 1 Patients characteristics at
inclusion Median age at inclusion (years) 74 [46–88]




Hurthle cell 1 (10%)





Median time since total thyroidectomy (years) 7 [1–16]
Median delay since discovery of 1st bone metastases (years) 6 [0–17]
Median time since last 131I treatment (years) 3 [0–10]
Median number of 131I treatments 4 [2–8]
Median total cumulated activity (GBq) 15 [7.4–35.6]
Treatment of bone metastases





Rank ligand inhibitors 2 (20%)
Presence of visceral metastases at inclusion
Neck (lymph nodes) 1 (10%)
Lung 5 (50%)
Localization of bone metastases
Axial 10 (100%)
Peripheral skeleton 3 (30%)
Number of patients according to target lesion type
Only lytic 5 (50%)
Only mixed 1 (10%
Lytic+mixed 2 (20%)
Lytic + sclerotic + mixed 2 (20%)
Patients with negative Ab anti Tg 7
Median Tg levels at baseline (ng/ml) 14.645 [486–23.200]
Patients with positive Ab anti Tg 3
Median value of Abanti Tg (>4 UI/mL) 25 [8–25]
Median ALP levels at baseline (UI/L) 62 [48–122]
Median b-ALP levels at baseline (U/L) 8 [0–22]
The results are reported by median (range)
ECOG Eastern Cooperative Oncology Group, Tg thyroglobulin, ALP alkaline phosphatase, Ab antibodies
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respectively. The patient that received only 3 Radium-223
treatments (patient n = 12) because of the occurrence of skel-
etal event had poorly differentiated carcinoma and received
previously a cumulated activity of radioactive iodine of
11.35 GBq. According to the type of lesions and the per-
patient response after the 6 administrations of Radium-223,
among patients with PD, 3/5 presented lytic target lesions
only, 1/5 mixed lesions only, and 1/5 lytic, mixed, and scle-
rotic lesions, respectively. Among the 4 patients with SD, 2/4
presented lytic lesions only and 2/4 both lytic and mixed le-
sions. The patient that received only 3 Radium-223 treatments
(patient n = 12) had lytic, sclerotic, and mixed lesions, respec-
tively. The per-lesion analysis response at 18F-FDG PET ac-
cording to the lytic/sclerotic/mixed status is presented in
Table 2. Histology, cumulative received radioactive iodine
activity, number and type of target lesions, SUL peak, and
TLG variations in a per-patient analysis are presented in
Supplementary Table 3.
Twenty-nine lesions were considered target lesions for
SUVmax evaluation at 18FNa PET/CT. The baseline medi-
an SUVmax for lesion was 17 (range: 4.8–41.6) and the
median total SUVmax was 48.9 (range:15.7–123.2). After
three administrations of Radium-223, tumor response was
SD in nine cases and PD in one. After six administrations
of Radium-223 in the nine evaluable patients, tumor re-
sponse was SD in eight cases and PR in one. The only
patient classified as PD at 3 months became SD at 6 months
(patient n = 4) and one patient classified as SD at 3 months
presented a PR at 6 months (patient n = 11). Both patients
presented with lytic lesion only. A comparison between
18F-FDG PET/CT and 18FNa PET/CT responses is summa-
rized in Supplementary Table 4. After three administra-
tions, 18F-FDG and 18FNA PET/CT were concordant in
five cases (4 SD and 1 PD) and discordant in the remaining
five cases (5 PD at 18F-FDG PET classified as SD at 18FNa
PET/CT) (Fig. 3). After six administrations, 18F-FDG and
18FNa PET/CT were concordant in three cases (all SD) and
Table 2 Summary of response after 3 and 6 administrations of Radium-223 in the entire cohort of patients in lesion-by-lesion analysis according to
PERCIST criteria on 18F FDG PET/CT and according to SUVmax on 18FNa PET/CT
Variable Response Lytic Sclerotic Mixed Not interpretable
18FDG PET 18FNa PET 18FDG PET 18FNa PET 18FDG PET 18FNa PET 18FDG PET 18FNa PET
3 months evaluation Number 15 17 2 1 10 10 1 1
PR 1 0 0 0 1 0 0 0
SD 8 15 1 1 8 10 1 1
PD 6 2 1 0 1 0 0 0
Number 12 15 1 1 9 10 1 1
6 months* evaluation PR 0 2 0 0 0 2 0 0
SD 9 13 1 1 5 8 0 1
PD 3 0 0 0 4 0 1 0
PERCIST PET Response Criteria In Solid Tumor
*1 patient was not evaluable at 6 months and the total number of lesions is reduced from 28 to 23 lesions between 3 and 6 months at 18 F-FDG PET/CT
and from 29 to 27 at 18 F-FNa PET/CT
Fig. 2 Waterfall plot of total SULpeak variation at 3 months and at
6 months for each included patient according to response criteria used
for 18F-FDG PET/CT. Disease progression (red column) was defined also
in case of SULpeak increase less than 30% but increase > 75% of total
lesion glycolysis (TLG) or in case of appearance of new lesions
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discordant in the remaining six cases (5 PD at 18F-FDG
PET/CT classified as SD at 18FNa PET/CT and 1 SD at
18F-FDG PET classified as PR at 18FNa PET/CT). The per-
lesion analysis response at 18F-FNa PET according to the
lytic/sclerotic/mixed status is presented in Table 2.
Regarding bone scan, the same target lesions analyzed at
18F-FDG PET were considered and all presented a
moderate/intense tracer uptake. Tumor response after three
and six treatments of Radium-223 was SD in all the cases.
Clinical benefits
A complete disappearance of pain was observed in three
among the eight evaluable patients after three administrations
of Radium-223 and in two among the seven evaluable patients
after six administrations, whereas the remaining patients had
no clinical response. Analgesic drugs were stopped in two of
the seven treated patients after three administrations of
Radium-223 and were continued otherwise. ECOG status
Fig. 3 Baseline, 3 months and 6 months. (A) 18F-FDG PET/CT. (B)
18FNa PET/CT. and (C) 99mTc-HMDP bone scintigraphy. The patient
presented at baseline 4 bone target lesions. Total SULpeak and total TLG
at baseline 18F FDG PET were 39.1 and 335.3, respectively. He was
defined as PD for ΔSULpeak of + 33% at 3 and 6 months (ΔTLG of +
51% and + 72%, respectively). Total SUVmax at baseline 18FNa PET/CT
was 107.4. He was defined with SD with ΔSUVmax of − 21.5% and −
22% after 3 and 6 administrations of Radium-223, respectively. Disease
was considered stable at bone scintigraphy both at 3 and 6 months
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showed an improvement of at least one point in two patients
after three and six Radium-223 administrations, whereas it
remained stable in the other patients.
Biological markers
Among the seven patients without Tg antibodies, a significant
decrease (> 50%) in Tg level was observed in three cases after
one, four, and six administrations of Radium-223. During fol-
low-up, no prolonged response according to Tg levels was
reported. At 3 months follow-up, Tg levels were stable com-
pared to baseline in 5 patients and progressive compared to
baseline in 2 patients. ALP and b-ALP available in seven
patients were in the normal range at baseline in all cases
(Table 1). Their levels decreased significantly in three cases;
none of them was under treatment with denosumab or
bisphosphonate.
Skeletal-related events
Skeletal-related events were observed in 6 patients (local pro-
gression with indication for local treatment in five cases and
pathological fracture in one case), five among them treated
with denosumab or bisphosphonate. The median time without
skeletal event was 12.1 months (IC 95% 3.5—not evaluable).
The Kaplan-Meier curve representing the rate without SRE
according to time is presented in Fig. 4.
Safety
During the 6 months of the Radium-223 treatment period, all
patients experienced at least one adverse event. The majority
of adverse events (70 of 77 events [91%]) were grade 1–2
events consisting mainly in bone pain (n = 8), asthenia (n =
8), anemia (n = 5), lymphopenia (n = 4), leukopenia (n = 4),
nausea (n = 5), pain (n = 5), febrile neutropenia (n = 3), and
thrombocytopenia (n = 3). There were seven grade 3 adverse
events consisting in lymphopenia (n = 2), leukopenia (n = 1),
febrile neutropenia (n = 1), abscess (n = 1), thrombocytopenia
(n = 1), and bone pain (n = 1) (Table 3).
In three patients, serious AE occurred after the 6-month
treatment period and were reported after the last patient inclu-
sion. These patients developed a myeloid leukemia: one acute
myeloid leukemia with a (8;16) cytogenetic translocation, one
promyelocitic leukemia with a (15;17) translocation, and one
chronic myeloid leukemia with a (9;22) translocation occurred
9, 19, and 8 months after the last Radium-223 administration,
respectively (Supplementary Table 5). The first patient
(67 years) with an acute myeloid leukemia received prior to
enrolment 3 administrations of RAI for a total cumulative
activity of 11.1 GBq and one field of external radiation treat-
ment for bone metastases. She was diagnosed 9 months after
her last Radium-223 administration and died 4 months after
the diagnosis of AML. The second patient (84 years) with a
promyelocytic leukemia received prior to enrolment 8 admin-
istrations of RAI for a total cumulative activity of 29.6 GBq
and 3 fields of external radiation treatments for bone metasta-
ses. He was diagnosed 19 months after his last Radium-223
administration and died 2 months after the diagnosis of the
leukemia. The third patient (77 years) with a chronic myeloid
leukemia received prior to enrolment 5 administrations of RAI
for a total cumulative activity of 20.3 GBq and one field of
external radiation treatment for bone metastases. He was di-
agnosed 8 months after his last Radium-223 administration.
Three months after diagnosis of chronic myeloid leukemia, he
is still alive and being treated with imatinib. All 3 patients
Fig. 4 Kaplan-Meier estimation
of probability of skeletal event
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presented hematological adverse events during Radium 223
treatment. The first patient presented a grade 3 thrombocyto-
penia and a grade 2 leukopenia, lymphopenia, and febrile
neutropenia. The second patient presented a grade 3 leukope-
nia, lymphopenia, and febrile neutropenia and a grade 1
thrombocytopenia. The last patient presented a grade 1 leuko-
penia and neutropenia.
Overall survival
After a median follow-up of 17.7 months from the last
Radium-223 administration, 4/10 patients died. The median
overall survival was 21.5 months (IC 95% = [17.5–27.5]),
with a 1-year survival of 100% and a 2-year survival of
33%. The reasons for death were promyelocytic leukemia in
one case and acute myeloid leukemia in one case. The remain-
ing two patients died because of disease progression 13 and
16 months after the last Radium-223 administration.
Discussion
In this first trial investigating the efficacy and safety of
Radium-223 in patients with bone metastases from RAIR thy-
roid cancer, there was no evidence of any metabolic response
at 18FDG PET/CT or significant clinical improvement.





Serious Adverse event N pat % N pat % N pat %
No Bone pain 8 80 . . 1 10
Asthenia 6 60 2 20 . .
Lymphopenia 2 20 2 20 2 20
Leukopenia 3 30 1 10 1 10
Pain 4 40 1 10 . .
Anemia 5 50 . . . .
Nausea 5 50 . . . .
Febrile neutropenia 2 20 1 10 1 10
Thrombocytopenia 3 30 . . . .
GGT increased 1 10 1 10 . .
Sore muscles 2 20 . . . .
Viral disease 2 20 . . . .
Diarrhea 2 20 . . . .
Incontinence 2 20 . . . .
Abscess . . . . 1 10
Bilirubin increased 1 10 . . . .
Creatinine increased 1 10 . . . .
HTA 1 10 . . . .
Hypertriglyceridemia 1 10 . . . .
Hyperuricemia 1 10 . . . .
Inguinal hernia surgery 1 10 . . . .
Neutropenia 1 10 . . . .
Paresthesia 1 10 . . . .
Rash pustular 1 10 . . .
Tachycardia 1 10 . . .
Urea increased 1 10 . . .
Vertigo 1 10 . . .
Alteration of the general condition 1 10 . . .
Anorexia 1 10 . . .
Constipation 1 10 . . .
Yes Thrombocytopenia* . . . 1 10
*Related to acute myeloid leukemia of the patient
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According to interim analysis, the trial was stopped after the
inclusion of the first ten patients.
Radium-223 has been approved by the FDA and EMA for
treatment of patients with symptomatic bone metastases from
mCRPC based on ALSYMPCA phase III trial results showing
a significant improvement of both overall survival and
prolonged time to first symptomatic skeletal events. Recently,
the ERA-223 study showed an increased number of skeletal
events in patients treated with the association of Radium-223
and abiraterone and it is actually reserved in case of progression
after at least two prior lines of systemic therapy for mCRPC
(other than LHRH analogues), or ineligible for any available
systemic mCRPC treatment [11, 20]. Nevertheless, Radium-
223 efficacy in prostate cancer is related to osteoblastic nature
of bone metastases, while there are few data on the efficacy of
Radium-223 in patients with other cancers with mixed or lytic
lesions. Some promising but still low evidence is available in
breast cancer patients. In an open-label phase II trial including
23 patients with breast cancer and mainly osteoblastic lesions,
Radium-223 significantly reduced uNTX-1 and b-ALP serum
levels and induced a 32% metabolic response rate (mRR) on
18F-FDG PET [13]. In a second phase II trial including 36
patients with breast cancer treated with Radium-223 in associ-
ation with hormonal therapy, disease control in 49% of patients
and a tumor response rate of 54% assessed by 18FDG PET/CT
6 months after last Radium-223 treatment have been reported
without grade 3/4 adverse events [16]. In a case report of a
single breast cancer patient with diffuse bone metastases,
Radium-223 provided bone pain improvement, a decrease in
tumor markers with metabolic response at 18FDG PET/CT, and
at a lower grade at 18FNa bone PET/CT [14]. In another case
report of a single breast cancer patient with osteolytic metasta-
ses, Radium-223 uptake was demonstrated in osteolytic metas-
tases with perfect overlap with the regions of osteolysis previ-
ously detected by scintigraphy, indicating a possible therapeutic
effect in this setting [15]. Other trials investigating the efficacy
of Radium-223 in association with other systemic treatments in
non-prostate cancer are ongoing (NCT 02258451, NCT
02258464, NCT 02880943).
Radium-223 is well known to distribute in bone formation
area at 99mTc-HMDP bone scintigraphy, and this is the tech-
nique of choice to select patients and to monitor response in
prostate cancer clinical trials [21]. In our study, 18F-FDG PET/
CT was chosen as principal criteria because most RAI refrac-
tory thyroid cancers are 18F-FDG avid [22]. 18F-FDGPET/CT
has indeed been used also for breast cancer trials [13, 16].
Considering SUL peak and TLG as parameters according to
PERCIST criteria, no tumor response was observed. PD was
seen in 6 cases after three and in 5 cases after six administra-
tions of Radium-223. Otherwise, SD was observed. Even if
only SUL peak had been taken into account to define tumor
response because of the lower reproducibility of TLG evalu-
ation, there would have been 4 PD and 6 SD after three
Radium-223 administrations, which does not change the re-
sults of the study.
The distribution of lesions was heterogenous according to
disease response in the per-patient evaluation. Among the 28
target lesions considered for analysis at 18FDG PET, 15 were
lytic, 10 were mixed, and only two were sclerotic and 1 not
evaluable. However, the rate of tumor response in mixed and
sclerotic lesions was not higher than in lytic lesions, but the
small number of lesions analyzed does not allow any firm
conclusion. Nevertheless, all the patients were screened before
starting treatment to verify the presence of bone remodeling
tracers uptake (18 FNa PET and 99mTc HMDP) and only pa-
tients with 18FNa and 99mTc-HMDP uptake in bone lesions
were included and considered for Radium-223 treatment.
18FNa PET/CT has been proposed to substitute bone scintig-
raphy to predict and to evaluate the response to treatment in
patients with prostate cancer [23]. According to 18FNa PET, only
one PR was observed after six administrations of Radium-223,
whereas on 99mTc HMDP bone scintigraphy, no PR was ob-
served, and the best response was only SD. In summary, 18F-
FDG PET/CT detected more PD compared to other methods.
Furthermore, one case defined as PD at 18F-FDG PET after three
administrations was finally classified as SD after six administra-
tions, which might be linked to a flare-up phenomenon [24].
Additionally, the clinical benefit was limited with an objec-
tive response in pain scale and a decrease in Tg value in three
patients. ALP and b-ALP decreased in three cases only, most
probably due to a decrease in the physiologic osteoblastic ac-
tivity since the values of baseline ALP and b-ALP were within
the normal range. The rate of skeletal events was also high with
six (60%) patients developing a skeletal event, after three ad-
ministrations of Radium-223 in 1 case and after a median time
from inclusion of 12.1 months in the other 5 patients.
According to the safety report, several hematological
events have been observed during the treatment period, main-
ly of grade 1–2. Nevertheless, during follow-up, two acute
rapidly fatal myeloid leukemias and one chronic myeloid leu-
kemia were observed. Hematological toxic effects are well
known in patients treated with bone-targeting radionuclides
[25]. Nevertheless, our data are in contrast with the long-
term safety data of patients with prostate cancer treated with
Radium-223 [26]. Only sporadic long-term hematological
malignancies have been reported, despite dosimetry studies
that show that an overall administered activity of 23 MBq in
a 70-kg patient after six administrations of Radium-223 would
result in an absorbed alpha dose of approximately 1.7–2.0 Gy
to the red bone marrow [27, 28]. A major difference with our
study is that our patients were previously exposed to high
cumulative activities of RAI combined with external beam
radiation, but the excess in the relative risk of leukemia report-
ed in such patients is much lower than what is observed in the
present study. An excess of relative risk of 0.59 per cumula-
tive activity in GBq of RAI administered was reported in
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Rubino et al.’s study in patients treated with external radio-
therapy [29]. Furthermore, grade 1–3 hematological toxicities
during treatment were in favor of a significant effect of bone
marrow irradiation by Radium-223. The three leukemias oc-
curred 8 to 19 months after the first Radium-223 treatment, an
interval of time in agreement with radiation-induced leuke-
mias observed after the Japanese atomic bombings and after
external beam radiation therapy in cancer patients [30]. Based
on this interval of time and on the translocations observed, we
considered that the leukemias were indeed related to the
Radium-223 administrations [31]. The occurrence of second-
ary blood malignancies that are rapidly fatal is indeed a major
concern in the setting of radionuclide therapy [32]. For 177Lu-
octreotate peptide receptor radionuclide therapy, it ranges in
most studies between 1 and 5% but was reported to be as high
as 20% in neuroendocrine tumor patients heavily pretreated
with alkylating chemotherapy [33, 34].
Even if the nature of the study is prospective, some limita-
tions should be taken into account. First, it included a small
number of patients with limited statistical analysis. Regarding
the limited number of included patients, the trial was stopped
according to the initial design due to the absence of response
to Radium-223 at the interim analysis. First, the observation of
severe hematological toxicity after the last inclusion in these
heavily pretreated patients supported accrual closure. Second,
the occurrence of hematological toxicities has been probably
underestimated in patients receiving subsequent treatment
with alpha emitters after radioactive iodine and external radio-
therapy, but it is in our opinion an important information for
future studies in the field of radiometabolic treatment. Finally,
the criteria used for disease response such as PERCIST in
18FDG PET could not be the most appropriate for bone-
seeking radiopharmaceutical efficacy evaluation. On the other
hand, considering 18FNa PET/CT and bone scintigraphy re-
sults, only 1 partial response and stable disease in all remain-
ing cases were reported confirming the absence of Radium-
223 efficacy in this subset of patients.
Conclusions
This trial shows the absence of efficacy of Radium-223 in
patients with bone lesions from thyroid cancer and a high
incidence of hematological leukemia toxicity in heavily
pretreated patients.
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